Predicting Pathological Complete Response Following Neoadjuvant Therapy in Patients With Breast Cancer: Development of Machine Learning-Based Prediction Models in a Retrospective Study.
Journal:
JMIR cancer
Published Date:
Jul 18, 2025
Abstract
BACKGROUND: Breast cancer is the most prevalent form of cancer worldwide, with 2.3 million new diagnoses in 2022. Recent advancements in treatment have led to a shift in the use of chemotherapy-targeted immunotherapy from a postoperative adjuvant to a preoperative neoadjuvant approach in select cases, resulting in enhanced survival outcomes. A pathological complete response (pCR) is a critical prognostic marker, with higher pCR rates linked to improved overall and disease-free survival.